Apogee Therapeutics closed at $132.55, surging 46.66% after AbbVie’s proposed $135.11-per-share cash acquisition fueled a sharp revaluation. The stock is now trading just below the offer price, indicating the market is pricing in a high probability of deal completion. Investor focus is on whether the transaction closes in the near term.
Apogee Therapeutics closed at $132.55, surging 46.66% after AbbVie’s proposed $135.11-per-share cash acquisition fueled a sharp revaluation. The stock is now trading just below the offer price, indicating the market is pricing in a high probability of deal completion. Investor focus is on whether the transaction closes in the near term.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
strongly positive
Sentiment Score
0.78
Ticker Sentiment
